Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2025-08-22 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
重大信息内部报告制度（2025年8月）
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '重大信息内部报告制度' (Major Information Internal Reporting System) for Chongqing Boteng Pharmaceutical Technology Co., Ltd., dated August 2025. It outlines the procedures, responsibilities, and scope for internal reporting of major information that could affect the company's stock price or trading. The content focuses on governance, internal controls, confidentiality, and reporting obligations related to material information disclosures. There are no financial statements, earnings data, audit opinions, or regulatory filings of financial results. It is not an announcement of a report but a governance and compliance policy document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-22 Chinese
信息披露暂缓与豁免管理制度（2025年8月）
Regulatory Filings Classification · 95% confidence The document is a detailed internal policy and procedural manual regarding the management of information disclosure delays and exemptions for a company, including legal references, approval processes, confidentiality commitments, and internal controls. It does not contain financial statements, earnings data, voting results, or any form of report publication announcement. It is a regulatory compliance and governance-related document outlining how the company manages sensitive information disclosure under applicable laws and stock exchange rules. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit into more specific categories like Annual Report, Interim Report, or Governance Information.
2025-08-22 Chinese
外汇衍生品交易业务管理制度(2025年8月）
Governance Information Classification · 95% confidence The document is titled as a management system or policy document for foreign exchange derivative trading business of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It outlines principles, approval procedures, management, risk reporting, and disclosure requirements related to foreign exchange derivative transactions. It is a regulatory or internal governance document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a notice or announcement of a report. It is a governance or management framework document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2395 characters, which is relatively short but contains substantive governance content, not just an announcement or certification.
2025-08-22 Chinese
互动易平台信息发布及回复内部审核制度（2025年8月）
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '互动易平台信息发布及回复内部审核制度' (Interactive Easy Platform Information Release and Reply Internal Review System) issued by 重庆博腾制药科技股份有限公司. It outlines rules and procedures for communication with investors via the Shenzhen Stock Exchange's interactive platform, including compliance with securities laws and internal governance. There is no financial data, no report or announcement of financial results, no voting results, no management changes, no legal proceedings, no capital changes, and no other typical report content. The document is a governance-related internal regulation about investor communication and information disclosure practices. It is not a report, announcement, or financial filing but a governance information document. Therefore, the appropriate classification is Governance Information (CGR). The document length is 2337 characters, which is consistent with a policy document rather than a full report.
2025-08-22 Chinese
关联交易决策制度（2025年8月）
Governance Information Classification · 95% confidence The document is titled as a decision system for related party transactions of Chongqing Boteng Pharmaceutical Technology Co., Ltd., dated August 2025. It contains detailed internal rules and procedures regarding related party transactions, including definitions, decision-making authority, disclosure requirements, and compliance with laws and regulations. It is a governance-related document outlining company policies and procedures rather than a financial report, earnings release, or announcement. It does not contain financial statements or audit results. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-22 Chinese
公司章程修正案
Governance Information Classification · 100% confidence The document is a detailed amendment to the company's articles of association (公司章程修正案), which outlines the company's internal rules, governance structure, shareholder rights, board responsibilities, and other governance-related provisions. It does not contain financial statements, audit opinions, earnings data, or other financial performance information. Instead, it focuses on the governance framework and corporate bylaws. Therefore, this document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance content, confirming it is not a mere announcement or a short notice but a full governance document.
2025-08-22 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.